Follow
David Ross
David Ross
SAHMRI and Centre for Cancer Biology
Verified email at sa.gov.au
Title
Cited by
Cited by
Year
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
DM Ross, S Branford, JF Seymour, AP Schwarer, C Arthur, DT Yeung, ...
Blood, The Journal of the American Society of Hematology 122 (4), 515-522, 2013
8522013
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
AA Wylie, J Schoepfer, W Jahnke, SW Cowan-Jacob, A Loo, P Furet, ...
Nature 543 (7647), 733-737, 2017
5092017
Moving treatment-free remission into mainstream clinical practice in CML
TP Hughes, DM Ross
Blood, The Journal of the American Society of Hematology 128 (1), 17-23, 2016
3702016
Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure
TP Hughes, MJ Mauro, JE Cortes, H Minami, D Rea, DJ DeAngelo, ...
New England Journal of Medicine 381 (24), 2315-2326, 2019
3632019
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR
DM Ross, S Branford, JF Seymour, AP Schwarer, C Arthur, PA Bartley, ...
Leukemia 24 (10), 1719-1724, 2010
3392010
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study
A Hochhaus, T Masszi, FJ Giles, JP Radich, DM Ross, ...
Leukemia 31 (7), 1525-1531, 2017
3122017
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
S Branford, DT Yeung, DM Ross, JA Prime, CR Field, HK Altamura, ...
Blood, The Journal of the American Society of Hematology 121 (19), 3818-3824, 2013
2252013
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
S Branford, DT Yeung, WT Parker, ND Roberts, L Purins, JA Braley, ...
Blood, The Journal of the American Society of Hematology 124 (4), 511-518, 2014
2242014
Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease
S Branford, P Wang, DT Yeung, D Thomson, A Purins, C Wadham, ...
Blood, The Journal of the American Society of Hematology 132 (9), 948-961, 2018
1842018
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study
DM Ross, T Masszi, MT Gómez Casares, A Hellmann, J Stentoft, ...
Journal of cancer research and clinical oncology 144, 945-954, 2018
1542018
Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib
CY Cheah, K Burbury, JF Apperley, F Huguet, V Pitini, M Gardembas, ...
Blood, The Journal of the American Society of Hematology 123 (23), 3574-3577, 2014
1412014
Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL
DM Ross, S Branford, S Moore, TP Hughes
Leukemia 20 (4), 664-670, 2006
1142006
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
DT Yeung, MP Osborn, DL White, S Branford, J Braley, A Herschtal, ...
Blood, The Journal of the American Society of Hematology 125 (6), 915-923, 2015
1092015
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
EJ Duncavage, A Bagg, RP Hasserjian, CD DiNardo, LA Godley, ...
Blood, The Journal of the American Society of Hematology 140 (21), 2228-2247, 2022
932022
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
S Verstovsek, AT Gerds, AM Vannucchi, HK Al-Ali, D Lavie, ...
The Lancet 401 (10373), 269-280, 2023
902023
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells
DM Ross, IS Pagani, N Shanmuganathan, CH Kok, JF Seymour, AK Mills, ...
Leukemia 32 (12), 2572-2579, 2018
792018
Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR‐ABL DNA
PA Bartley, DM Ross, S Latham, MH Martin‐Harris, B Budgen, V Wilczek, ...
International journal of laboratory hematology 32 (6p1), e222-e228, 2010
712010
Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome
D Singhal, MM Kutyna, R Chhetri, LYA Wee, S Hague, L Nath, SV Nath, ...
Haematologica 102 (12), 2021, 2017
692017
Successful treatment‐free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells
YD Irani, A Hughes, J Clarson, CH Kok, N Shanmuganathan, DL White, ...
British Journal of Haematology 191 (3), 433-441, 2020
632020
How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia
DM Ross, TP Hughes
British journal of haematology 166 (1), 3-11, 2014
632014
The system can't perform the operation now. Try again later.
Articles 1–20